Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study

doi:10.12998/wjcc.v9.i31.9417

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 31

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4255)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

195

WORD

127

HTML

1881

Figures (1-4)

255

Tables (1-4)

592

Sum=3050

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

370

Download

835

Sum=1205

Nov 6, 2021 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Nov 6, 2021; 9(31): 9417-9430
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9417

Table 1 Clinical characteristics of recruited patients

Characteristics	Patient numbers (%) (n = 116)
Age, median (range)	58.5 (19-92)
Years of diagnosis
1999-2009	36 (31.8)
2009-2019	80 (68.2)
Sex
Male	72 (62.1)
Female	44 (37.9)
Presentation
Abdominal pain	58 (50.0)
Fatigue	21 (18.1)
Nausea and vomiting	13 (11.2)
Anorexia	7 (6.0)
Hepatomegaly	53 (45.6)
Splenomegaly	9 (7.7)
Asymptomatic	14 (12.0)
Lesion
Single/multiple/diffused/bulky	58 (50.0)/23 (19.8)/33 (28.4)/29 (25.0)
Lactate dehydrogenase
Elevated/normal	55 (47.4)/58 (52.6)
B symptoms
Loss of weight/fever/night sweat	39 (33.6)/36 (31.0)/9 (7.7)
Infection
HBV/HCV/EBV	15 (12.9)/12 (10.3)/9 (7.7)
Immunosuppressive status
Autoimmune disease	13 (11.2)
Rheumatic Arthritis	7 (6.0)
HIV	7 (6.0)
Differential diagnosis
HCC	21 (18.1)
Metastasis	18 (15.5)
Abscess or infection	12 (10.3)
ICC	10 (8.6)
Cholecystitis	5 (4.3)
Pseudolymphoma	4 (3.4)
Hemangioma	4 (3.4)
Treatment
Surgery	36 (31.0)
Chemotherapy/R-CHOP/CHOP	86 (74.1)/55(47.4)/10(8.6)
Radiotherapy	6 (5.1)
PHL subtypes
B cell lymphoma	99 (85.3)
DLBCL/MALT/HL/BL/FL/HGBCL	72 (62.1)/14(12.0)/4(3.4)/3(2.5)/3(2.5)/3(2.5)
T cell lymphoma	7 (6.0)
Other unclassified¹	10 (11.6)
Region
Asia	72 (62.1)
Japan/China/India/South Korea	24 (20.6)/17(14.6)/16(13.7)/8(6.8)
Other	7 (6.0)
Europe	20 (17.2)
North America	15 (12.9)

¹The diagnosis of primary hepatic lymphoma was confirmed, but there was no specific subtype classification. HBV: Hepatitis B virus; HCV: Hepatitis C virus; EBV: Epstein-Barr virus; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; R-CHOP: Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone; DLBCL: Diffuse large B-cell lymphoma; MALT: Mucosa-associated lymphoid tissue lymphoma; TCL: T cell lymphoma; HL: Hodgkin lymphoma; BL: Burkitt lymphoma; FL: Follicular lymphoma; HGBCL: High grade B cell lymphoma; Other: 1 primary plasmacytic hepatic lymphoma and 1 anaplastic large cell lymphoma.

Citation: Hai T, Zou LQ. Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study. World J Clin Cases 2021; 9(31): 9417-9430
URL: https://www.wjgnet.com/2307-8960/full/v9/i31/9417.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i31.9417